# Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

> **NCT01160718** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 46 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** fulvestrant
- **DRUG:** selumetinib

## Key facts

- **NCT ID:** NCT01160718
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-12
- **Final completion:** 2016-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160718, "Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01160718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*